Disappointing Q2 Results Send PI Industries Down 15% to Six-Year Low

PI Industries’ Margin Squeeze Puts Export Weakness in Focus

A steep fall in profitability, rather than revenue alone, has sharpened questions about the agrochemicals group’s near-term recovery.

A sharp earnings decline drives the market repricing

PI Industries reported revenue of ₹1,702 crore in Q2FY27, down 9 per cent year on year. The larger setback came below the revenue line: EBITDA fell 57 per cent to ₹232.7 crore, while profit after tax dropped 70 per cent to ₹122 crore. EBITDA margin contracted by 1,524 basis points to 13.7 per cent.

The share price fell as much as 15 per cent to ₹1,859.25, its lowest level since September 2020, and slipped below its previous low of ₹2,006. At 9:59 a.m., it was down 14 per cent at ₹1,879.80, while the Sensex was up 2 per cent. Combined trading volume of 2.18 million shares on the NSE and BSE was nearly twice the average, pointing to heightened investor activity. The stock had also fallen to less than half its 52-week high of ₹3,829.

Export softness and costs hit margins together

The company cited higher input costs and pricing pressure linked to El Niño and genericisation as factors behind the margin decline. Analysts at ICICI Securities also pointed to subdued global demand affecting agrochemical exports. Under those conditions, higher raw-material costs and pricing pressure were not actively passed through, according to the brokerage’s assessment.

This combination matters because a decline in sales can be compounded when the company cannot protect unit economics through pricing. PI Industries also reported higher overheads, reflecting continued investment in new businesses and research and development, new molecule launch expenses and increased energy costs. Such spending may support future opportunities, but in this quarter it added to the strain on earnings.

Growth pockets remain, but are not yet offsetting the pressure

The results were not uniformly weak across the business. ICICI Securities said the pharma CDMO operation grew after PI began commercial GMP manufacturing of Galidesivir API. In domestic agriculture, the biologicals business expanded by more than 45 per cent as the company widened its crop reach and product portfolio.

The brokerage also noted that PI had onboarded large pharmaceutical customers and was working on two strategic products for long-term contracts, indicating continued traction in its CDMO pipeline. These developments may diversify the sources of growth, but they do not remove the immediate challenge of weaker agrochemical exports and rising input costs. The pace at which new business converts into sustained earnings will be important to watch.

Cash and investment provide context, not a near-term fix

PI Industries reported a cash balance of ₹3,573 crore and total capital expenditure of ₹567 crore in H1FY27. The balance sheet resources and spending reflect ongoing investment in the business, but investors will still look for evidence that these investments can support growth without leaving profitability exposed to prolonged weak demand or cost escalation.

ICICI Securities described near-term performance as challenging and said it was awaiting management commentary. For investors, clarity on export demand, pricing conditions and the ability to manage input costs will help determine whether this quarter represents a temporary setback or a more persistent earnings concern.

Key Highlights

• Q2FY27 revenue declined 9 per cent year on year to ₹1,702 crore.
• EBITDA fell 57 per cent to ₹232.7 crore, with margin down to 13.7 per cent.
• Profit after tax dropped 70 per cent to ₹122 crore.
• Domestic agri biologicals grew more than 45 per cent; commercial GMP manufacturing of Galidesivir API began.
• The company reported ₹3,573 crore in cash and ₹567 crore of H1FY27 capex.

Investor Note: The sharp share-price decline reflects the market’s response to a significant deterioration in quarterly earnings, but one quarter alone does not establish the longer-term trajectory. Investors may want to assess management’s explanation of demand, pricing and cost trends alongside evidence that the CDMO and biologicals businesses can contribute meaningfully over time.